S

SCYNEXIS

D
SCYX
USD
0.01
(0.7519%)
Market Closed
721.00
Volume
-0.31
EPS
-
Div Yield
-1.810811
P/E
50,727,660.42
Market Cap
Today
0.7519%
1 Week
-1.832%
1 Month
-10.067%
6 Months
-27.568%
12 Months
-28.342%
Year To Date
-39.640%
All Time
0%

Title:
SCYNEXIS

Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Do you need help or have a question?